

Amendments to the Claims

1. (currently amended) A method of screening for potential [therapeutics] vaccine targets for infectious diseases, comprising:

(a) identifying host cell gene products selected from the group consisting of: host cell gene products which are upregulated during infection and host cell gene products which are expressed only during infection; and

(b) screening said host cell gene products for immunogenicity; wherein said gene products which are immunogenic in said host are potential vaccine targets for infectious disease during which such upregulation or expression occurs.

2. (previously amended) The method of claim 1, wherein said host cell gene products which are upregulated are expressed at a lower level in uninfected cells than in infected cells of the same type.

3. (original) The method of claim 1, wherein said host cell gene products which are upregulated are not expressed at all in uninfected cells of the same type.

4. (original) The method of claim 1, wherein said infection is infection with human immunodeficiency virus (HIV).

5. (original) The method of claim 1, wherein said screening for immunogenicity is screening for a cytotoxic T lymphocyte (CTL) response.

6. (original) The method of claim 1, wherein said host cell gene products of (a) are identified using ordered microarrays of nucleic acids.

B1

7. (original) The method of claim 1, wherein said host cell gene products of (a) are identified using subtractive hybridization.